Form 4: Tempest Therapeutics CEO Boosts Stake with $500K Share Purchase

Tempest Therapeutics' CEO and President, Matthew Angel, acquired 231,482 shares of common stock for $2.16 per share, signaling strong insider confidence.

Summary

• Matthew Angel, CEO, President, Director, and 10% Owner of Tempest Therapeutics, Inc. (TPST), acquired 231,482 shares of common stock.
• The transaction occurred on March 24, 2026, at a price of $2.16 per share, totaling approximately $500,000.
• These shares are indirectly held by Factor Bioscience Inc., where Mr. Angel serves as chief executive officer and chairman of the board of directors.
• Mr. Angel disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.
• Following this transaction, Mr. Angel's indirect beneficial ownership through Factor Bioscience Inc. is 231,482 shares.
• Additionally, Mr. Angel directly beneficially owns 4,837,070 shares, which reflects a pro rata distribution from Erigen LLC and was not a new acquisition requiring a Section 16 report.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal. Insider buying, particularly by a CEO, often suggests confidence in the company's future and can be a precursor to positive developments or an indication of perceived undervaluation.

Positives

• A significant insider purchase by the CEO and President, Matthew Angel, indicates strong confidence in the company's future prospects.
• The acquisition of 231,482 shares at $2.16 per share represents a substantial personal investment by a key executive.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase can be interpreted as a positive signal regarding management's outlook on the company's future performance.

Industry Context

StockSavvy.ai notes that insider buying, especially by a CEO, is often viewed by the market as a strong indicator of management's belief in the company's undervaluation or future growth prospects. In the biotechnology sector, where companies often face high R&D costs and regulatory hurdles, such a vote of confidence from leadership can be particularly impactful, potentially signaling positive internal developments or a favorable outlook on upcoming milestones.

Related Party Transactions

• The transaction involves Matthew Angel, CEO, President, Director, and 10% Owner, acquiring shares of Tempest Therapeutics, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign, potentially increasing investor confidence and demand for the stock.
• Employees might interpret the CEO's investment as a sign of stability and belief in the company's long-term vision.

Key Dates

Recommendation

A significant insider purchase by the CEO, who is also a 10% owner, typically signals strong conviction in the company's future performance and potential undervaluation. This action by a key executive often precedes positive developments or improved financial results, making it a compelling 'buy' signal for seasoned investors.

Keywords

Tempest Therapeutics, TPST, Insider Buying, Matthew Angel, Common Stock, SEC Form 4, Biotechnology, Pharmaceuticals, Executive Ownership